Key facts
- Lario Therapeutics’s last known valuation is $16.2M (Mar 2025).
- It has raised $9.8M; the latest was Grant ($2.4M) in Feb 2026.
- Notable investors include Wellcome Trust, Axxam, Epidarex Capital, Epidarex Exeed, Michael J. Fox Foundation.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Lario Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Lario Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lario Therapeutics
Developer of a biopharmaceutical company designed for neurological disorders, specifically for epileptic patients. The company's platform offers therapies for severe paediatric epilepsies, enabling patients with epileptic conditions and Parkinson's disease to change their lives.
- Sector
- Healthcare
- HQ
- Edinburgh, United Kingdom
- Founded
- 2021
- Employees
- 5
- Website
- lariotx.com/
- Ownership
- Privately Held (backing)
Lario Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lario Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lario Therapeutics in its N-PORT filings yet. We sweep new filings monthly.